Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 11, 2013The Journal of PathologyOpen Access

Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes

View Full Paper
Ask AI
Bookmark
Share

Authors

BLBrian D. LehmannVanderbilt University Medical CenterJPJennifer A. PietenpolBreast Cancer Research Foundation

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Lehmann et al. (2013) studied this question.

synapsesocial.com/papers/6a0cb4dfe8a76b3043889b5bhttps://doi.org/10.1002/path.4280
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular mediators of tumor angiogenesis: Enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer1999 · 104 citations
  2. 2Comprehensive molecular portraits of human breast tumours2012 · 12,659 citations
  3. 3A clinically relevant gene signature in triple negative and basal-like breast cancer2011 · 337 citations
  4. 4Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer2013 · 754 citations
  5. 5A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas2012 · 201 citations